Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INAB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Allogeneic Gene-modified Gamma Delta T-cells | Glioblastoma | Phase 1/2 · NCT05664243 | Active not recruiting |
| Autologous genetically modified gamma-delta T… | Glioblastoma | Phase 1/2 · NCT05664243 | Active not recruiting |
| EAGD T-cell infusion (Expansion) | Acute Myeloid Leukemia | Phase 1 · NCT03533816 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INAB holds $14.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 11.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
Based on the Company’s business strategy, its existing cash of $ 14.0 million as of September 30, 2026 is not anticipated to fund the Company’s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INAB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Aaron G.L. Fletcher 10% owner · +3.26M options |
Insider | 8,600,001 | 79.57% | 2025-05-02 |
| Leslie W. Kreis 10% owner · +3.26M options Includes shares also reported by Aaron G.L. Fletcher, counted once |
Insider | 8,600,001 | 79.57% | 2025-05-02 |
| LYTTON LAURENCE W | 5%+ holder (13G) | 1,056,513 | 9.78% | 2026-06-30 |
| Stonepine Capital Management, LLC | Institution (13G, 5%+) | 1,007,990 | 9.33% | 2025-12-19 |
| Alyeska Investment Group, L.P. | Institution (13G, 5%+) | 966,381 | 8.94% | 2025-12-31 |
| Franklin Resources, Inc. | Institution (13G, 5%+) | 914,531 | 8.46% | 2025-12-31 |
| 683 Capital Management, LLC | Institution (13G, 5%+) | 770,445 | 7.13% | 2025-12-22 |
| William Tai-Wei Ho CEO, Director · +1.44M options |
Insider | 124,817 | 1.15% | 2025-12-22 |
| Peter C. Brandt Director · +85,150 options |
Insider | 98,690 | 0.91% | 2025-12-22 |
| Alan S. Roemer Director · +154,609 options |
Insider | 49,514 | 0.46% | 2025-12-22 |
| Patrick McCall CHIEF FINANCIAL OFFICER · +494,742 options |
Insider | 9,482 | 0.09% | 2025-12-22 |
| Kate Rochlin President and COO · +491,245 options |
Insider | 9,085 | 0.08% | 2025-12-22 |
Share count 10,808,292 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INAB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →